VA-DXC-TECHNOLOGY
DXC Technology (NYSE: DXC) today highlighted how it is helping enterprises accelerate the adoption of augmented reality (AR), virtual reality (VR) and mixed reality (MR) technologies to support immersive experiences in ways that can significantly improve productivity, quality and efficiency.
According to Gartner, by 2022, 70% of enterprises will be experimenting with immersive technologies for consumer and enterprise use, and 25% will have deployed them to production.* DXC is using AR, VR and MR technologies today to transform the future of work, and the company is seeing widespread implementation to improve safety, connect remote workers, assist with complex tasks and enhance training and collaboration – all in ways that drive business results and profitability.
“Digital transformation in the workplace is edging towards an inflection point as enterprises are incorporating immersive solutions that connect the real world with the virtual world,” said Maria Pardee, DXC’s senior vice president and general manager, Workplace and Mobility. “DXC is using the power of AR, VR and MR to align the next-generation digital capabilities employees want so they can be more mobile and independent, with the critical security, production prowess and agility that today’s businesses demand.”
DXC Deploys Mixed Reality Employee Training at Water Treatment Leader Ixom
A market leader in water treatment and chemical distribution in Australia and New Zealand, Ixom turned to DXC to develop a custom training and assessment application using mixed reality on Microsoft HoloLens.
In the past, Ixom training and learning assessments were conducted at customer sites, requiring travel, scheduling and employee resources to mitigate safety risks. Now, using DXC’s mixed reality application for Microsoft HoloLens — custom built for Ixom — employees can participate in the required training and learning assessment at any Ixom office or remote location. The resulting increase in flexibility, autonomy and mobility has reduced Ixom travel costs, minimized employee safety risks and essentially eliminated the potential for exposure to hazardous materials during training at treatment facilities.
DXC is named a Leader in Advanced Digital Workplace Services Overall in the NelsonHall Evaluation & Assessment Tool (NEAT) Report 2019 . DXC is also an official partner in the Microsoft HoloLens Mixed Reality Partner Program, a status that reflects the company’s commitment to designing, developing and deploying solutions that help customers accelerate their digital transformations using mixed reality technologies.
The following DXC offerings enable immersive solutions using AR/VR technologies:
- DXC AR/VR services consist of AR/VR consulting, custom application development and system integration for a range of AR/VR devices including Microsoft HoloLens. DXC is also a Distributor Managed Partner for HoloLens 2 and provides services for MR business applications such as Microsoft Dynamics 365 Guides.
- DXC Remote Expert is an innovative AR solution that enables field workers in various industries (automotive, energy and utilities, manufacturing, travel and transportation, and healthcare) to display work instructions via a hands-free interface on their wearable or mobile devices and connect to experts at other locations when they need guidance.
- DXC Unified Endpoint Management enables enterprises to manage and secure mobile, PC, internet-of-things (IoT) and wearable devices in a single pane of glass. DXC’s collaboration with industry-leading technology partners, combined with DXC transformation, delivery and support services, provides users with secure and seamless access to enterprise applications, data and services independent of operating system, device type or location.
- DXC Workplace IoT enables enterprises to securely deploy and manage smart connected devices by combining IoT solutions, best practices, and market-leading platforms and technology partners to improve production, operational and human outcomes; automate processes with analytics; and gain situational awareness.
- DXC Open Health Connect creates a connected ecosystem that optimizes services for patients, healthcare providers and payers, using AR to provide better patient outcomes.
*Smarter With Gartner, Top 10 Strategic Technology Trends for 2019, October 2019, https://www.gartner.com/smarterwithgartner/gartner-top-10-strategic-technology-trends-for-2019 .
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005245/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom